Treosulfan has been incorporated into conditioning regimens over the last years. Our group has focused on the outcomes, firstly comparing it to reduced intensity conditioning, which was superior, and then trying to compare it to reduced toxicity conditioning other regimens without treosulfan. In this study we have tried to summarize the safety and efficacy of this regimen in our large patient population from our center...
Treosulfan has been incorporated into conditioning regimens over the last years. Our group has focused on the outcomes, firstly comparing it to reduced intensity conditioning, which was superior, and then trying to compare it to reduced toxicity conditioning other regimens without treosulfan. In this study we have tried to summarize the safety and efficacy of this regimen in our large patient population from our center. This has the advantage that it’s a single patient population with the same SOPs treated over the last 10 years. So our results are very encouraging for this patient population and I think they saw that with this regimen which is FT14 with a standard dosing of reduced toxicity we can have very well outcomes in myeloid malignancies and also expand the patient population that is eligible for transplant.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
